New and emerging prophylactic agents for migraine

CNS Drugs

Volumn 16, Issue 9, 2002, Pages 611-634

  Krymchantowski, Abouch V ^a,b   Bigal, Marcelo E ^c,d   Moreira, Pedro F ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b Program in Clinical Medicine   (Brazil)

^c NEW ENGLAND CENTER FOR HEADACHE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LISINOPRIL; MAGNESIUM; MONTELUKAST; PETASITES HYBRIDUS EXTRACT; PLANT EXTRACT; RIBOFLAVIN; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; ZONISAMIDE;

ALOPECIA; ASTHENIA; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD TOXICITY; BRAIN CORTEX; CALCIUM ANTAGONISM; CHRONIC PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; COMA; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DYSPEPSIA; GABAERGIC SYSTEM; HEADACHE; HEPATITIS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; MIGRAINE; NAUSEA; NERVE CELL INHIBITION; NERVE EXCITABILITY; PANCREATITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEDATION; SOMNOLENCE; TREMOR;

EID: 0036350518     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216090-00003     Document Type: Review

References (122)

1. Migraine heterogeneity, disability, pain intensity, and attack frequency and duration
2. Epidemiology of headache
3. Work-related disability: Results from the American migraine study
4. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
5. Preventive treatment of migraine: An overview
6. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
7. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks
8. Focal hyperemia followed by spreading oligoemia and impaired activation of rCBF in classic migraine
9. Cranial arteriovenous shunting: An in vivo animal model for migraine
10. Anticonvulsants in migraine prophylaxis
11. Cerebral and extracranial circulatory disturbances in migraine: Pathophysiological implications
12. Brain stem activation in spontaneous human migraine attacks
13. General principles of pharmacological treatment of migraine
14. Migraine: Diagnosis and treatment
15. Migraine prophylaxis: Indication for drug therapy
16. Anticonvulsants in migraine prophylaxis
17. Guidelines for controlled trials of drugs in migraine
18. Practice parameter: Evidence-based guidelines for migraine headache, an evidence-based review
19. Valproate: A new drug in migraine prophylaxis
20. Clinical pharmacology and therapeutic use of the new antiepileptic drugs
21. Models of primary generalized epilepsy
22. Migraine prophylaxis with divalproex
23. Safety of divalproex sodium in migraine prophylaxis: An open-label, long-term study: Long-term Safety of Depakote in Headache Prophylaxis Study Group
24. Valproate reduces C-Fos expression in trigeminal nucleus caudalis (TNC) after noxious meningeal stimulation
25. Actions of valproate and neurosteroids in a model of trigeminal pain
26. Sodium valproate in therapy of intractable headache with EEG changes
27. Valproate in the treatment of refractory recurrent headaches: A retrospective analysis of 207 patients
28. Sodium valproate in the prophylactic treatment of migraine: A doable-blind study versus placebo
29. Sodium valproate has a prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study
30. Divalproex sodium in migraine prophylaxis: A dose-controlled study: The Divalproex Sodium in Migraine Prophylaxis Study Group
31. A comparative study of propranolol and divalproex sodium in the prophylaxis of migraine
32. A rational guide to routine blood monitoring in patients receiving anti-epileptic drugs
33. Valproic acid hepatic fatalities: A retrospective review
34. Hematologic toxicity of sodium valproate
35. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy
36. Divalproex sodium in headache: Literature review and clinical guidelines
37. Lamotrigine: A review of its pharmacological properties and clinical efficacy in epilepsy
38. Anticonvulsant profile in mice of lamotrigine, a novel anticonvulsant
39. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II: Neurochemical studies on the mechanism of action
40. Extracellular changes of aspartate and glutamate during generation and during propagation of cortical spreading depression in rats
41. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: An open pilot study
42. Lamotrigine vs placebo in the prophylaxis of migraine with and without aura
43. Efficacy of gabapentin in migraine prophylaxis
44. Topiramate for migraine prophylaxis: A double-blind, randomized, placebo-controlled study
45. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine
46. Lamotrigine in the prophylactic treatment of migraine aura: A pilot study
47. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: An open pilot study
48. Lamotrigine-induced severe cutaneous adverse reactions
49. Epilepsy
50. Pharmacokinetics of new antiepileptic drugs
51. Gabapentin: Pharmacokinetics, efficacy, and safety
52. Gabapentin: Antiepileptic mechanism of action
53. The anticonvulsants in neuropathic painful syndromes
54. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain
55. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients
56. Gabapentin in migraine prophylaxis
57. Efficacy and tolerability of gabapentin in clinical practice
58. Topiramate as an inhibitor of carbonic anhydrase isoenzymes
59. Cellular actions of topiramate: Blockade of kainite-evoked inward currents in cultured hippocampal neurons
60. A and NMDA receptor channels by phosphorylation
61. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug
62. Clinical pharmacology of topiramate: A review
63. Topiramate in migraine prophylaxis: A pilot study
64. Topiramate in the treatment of chronic migraine and other headaches
65. The beneficial effect of slowing the initial titration rate of topiramate
66. Topiramate - Safety and tolerability
67. Letters to the editor
68. Presumed topiramate-induced bilateral acute angle-closure glaucoma
69. Topiramate: Side effect profile in double-blind studies
70. Topiramate a novel anti-epileptic agent
71. Bilateral angle-closure glaucoma and ciliary body swelling from topiramate
72. High-dose riboflavin as a prophylactic treatment of migraine: Results of an open pilot study
73. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorous 31 NMR spectroscopy
74. Chronic daily headaches (CDH) in children characteristics and treatment response
75. Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial
76. Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study
77. Magnesium in the prophylaxis of migraine: A double-blind, placebo-controlled study
78. Botulinum toxin type A as a migraine preventive treatment
79. Migraine prophylaxis: Other drugs
80. Migraine and magnesium: Eleven neglected connections
81. Low brain magnesium in migraine
82. The concept of migraine as a state of central neuronal hyperexcitability
83. Magnesium sulphate in the treatment of angiospasm
84. Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium
85. Botulin toxin type A (BOTOX) for treatment of migraine headaches: An open-label study
86. The origin, structure, and pharmacological activity of botulinum toxin
87. Commentary: The synaptic vesicle and its targets
88. Botulinum toxin type A (BTX-A) for migraine: An open label assessment
89. A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor
90. Tiagabine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy
91. An open-label trial of tiagabine for migraine prophylaxis
92. The prophylaxis of migraine with the GABA-agonist, tiagabine: A clinical report
93. Clinical aspects of prostaglandins and leukotrienes (LT) in migraine
94. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers
95. Montelukast in the prophylaxis of migraine: A potential role for leukotriene modifiers
96. Churg-Strauss Syndrome in patients receiving montelukast as treatment for asthma
97. Churg-Strauss Syndrome: Is there an association with leukotriene modifiers?
98. Evidence for a unique profile of levetiracetam in rodent model of seizures and epilepsy
99. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent
100. Levetiracetam as prophylaxis for resistant headaches
101. Levetiracetam for preventive treatment of migraine
102. Clinical pharmacology and therapeutic drug monitoring of zonisamide
103. Effects of zonisamide (AD-810) on tungstic acid gel-induce thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharge in cats
104. Preventive treatment of migraine with zonisamide
105. Zonisamide in the treatment of headache disorders
106. Methodological requirements for clinical trials in refractory epilepsies: Our experience with zonisamide
107. Zonisamide for add-on treatment of refractory partial epilepsy: A European double-blind trial
108. The broad substrate specificity of human angiotensin converting enzyme
109. Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers
110. Lisinopril: A review of its pharmacology and clinical efficacy in elderly patients
111. Sex-related pharmacokinetic and pharmacodynamic variations of lisinopril
112. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura
113. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomized, placebo-controlled, crossover study
114. The SF-36 heath survey: Development and use in mental health research and the IQOLA project
115. Butterbur, herbal help for migraine
116. Petasites hybridus: Ancient medicinal plant is effective prophylactic treatment for migraine
117. An extract of Petasites hybridus is effective in the prophylaxis of migraine
118. Efficacy of petasites (an extract from petasites rhizome) 50 and 75 mg for prophylaxis of migraine: Results of a randomized, double-blind, placebo controlled study
119. Inhibition of testosterone secretion by S-petasin in rat testicular interstitial cells